TY - JOUR T1 - Addition of Rituximab to Chemotherapy Reduced the Rate of Surgery for Gastric-DLBCL Without Increasing Early Mortality JF - Anticancer Research JO - Anticancer Res SP - 813 LP - 817 VL - 37 IS - 2 AU - PHILIPPE PROUET AU - SMITH GIRI AU - ERIC WIEDOWER AU - ANDREW FINTEL AU - GEORGE YAGHMOUR AU - ELENA PAULUS LAMB AU - JEREMIAH DENEVE AU - MARTIN FLEMING AU - PAXTON DICKSON AU - JASON C. CHANDLER AU - MIKE G. MARTIN Y1 - 2017/02/01 UR - http://ar.iiarjournals.org/content/37/2/813.abstract N2 - Background: We evaluated surgical trends for gastric diffuse large B-cell lymphoma (gDLBCL) before and after the approval of rituximab and whether an association of early mortality existed in patients treated after approval of rituximab. Patients and Methods: We utilized the Surveillance Epidemiology and End Results (SEER) 18 database to extract data on patients with gDLBCL diagnosed between 1983-2012. Primary site-specific cancer-directed surgery using SEER site-specific surgical codes and annual trends were analyzed. Patients were analyzed before and after 2006, the year rituximab gained U.S. Food and Drug Administration approval. Results: Joinpoint trend analysis showed the sharpest decline in surgical rates between 2000-2010. Adjusted surgical rates computed using poisson regression declined from 54.4% in 1983 to 6.9% in 2012, with an annual percentage change of −8.9% (95% confidence interval=−9.7% to −8.3%; p-value <0.01). No significant mortality increase at 30 and 60 days was found. Conclusion: While rituximab appears to have significantly changed how surgery is utilized for patients with gDLBCL, early mortality was unchanged. ER -